Literature DB >> 16997558

Polyoxometalates--a new class of potent ecto-nucleoside triphosphate diphosphohydrolase (NTPDase) inhibitors.

Christa E Müller1, Jamshed Iqbal, Younis Baqi, Herbert Zimmermann, Anita Röllich, Holger Stephan.   

Abstract

Polyoxotungstates were identified as potent inhibitors of NTPDases1, 2, and 3. The most potent compound was K(6)H(2)[TiW(11)CoO(40)], exhibiting K(i) values of 0.140 microM (NTPDase1), 0.910 microM (NTPDase2), and 0.563 microM (NTPDase3). One of the compounds, (NH(4))(18)[NaSb(9)W(21)O(86)], was selective for NTPDases2 and 3 versus NTPDase1. NTPDase inhibition might contribute to the described biological effects of polyoxometalates, including their anti-cancer activity.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16997558     DOI： 10.1016/j.bmcl.2006.09.003

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  54 in total

1.  Epitope mapping in cell surface proteins by site-directed masking: defining the structural elements of NTPDase3 inhibition by a monoclonal antibody.

Authors:  Vasily V Ivanenkov; Patrick A Crawford; Aimi Toyama; Jean Sévigny; Terence L Kirley
Journal:  Protein Eng Des Sel       Date:  2010-05-27       Impact factor: 1.650

2.  CD39 is a promising therapeutic antibody target for the treatment of soft tissue sarcoma.

Authors:  Gregory M Hayes; Belinda Cairns; Zoia Levashova; Lawrence Chinn; Myra Perez; Jan-Willem Theunissen; Sindy Liao-Chan; Abel Bermudez; Mark R Flory; Karl J Schweighofer; Edward H van der Horst
Journal:  Am J Transl Res       Date:  2015-06-15       Impact factor: 4.060

3.  Generation and characterization of polyclonal and monoclonal antibodies to human NTPDase2 including a blocking antibody.

Authors:  Julie Pelletier; Hervé Agonsanou; Ninotchska Delvalle; Michel Fausther; Mabrouka Salem; Brian Gulbransen; Jean Sévigny
Journal:  Purinergic Signal       Date:  2017-04-13       Impact factor: 3.765

4.  Role of P2 purinergic receptors in synaptic transmission under normoxic and ischaemic conditions in the CA1 region of rat hippocampal slices.

Authors:  Elisabetta Coppi; Anna Maria Pugliese; Holger Stephan; Christa E Müller; Felicita Pedata
Journal:  Purinergic Signal       Date:  2007-01-03       Impact factor: 3.765

5.  ATP hydrolysis pathways and their contributions to pial arteriolar dilation in rats.

Authors:  Francesco Vetri; Haoliang Xu; Lizhen Mao; Chanannait Paisansathan; Dale A Pelligrino
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-07-29       Impact factor: 4.733

6.  Various N-glycoforms differentially upregulate E-NTPDase activity of the NTPDase3/CD39L3 ecto-enzymatic domain.

Authors:  Alexander H Zhong; Z Gordon Jiang; Richard D Cummings; Simon C Robson
Journal:  Purinergic Signal       Date:  2017-09-27       Impact factor: 3.765

7.  Structural insight into signal conversion and inactivation by NTPDase2 in purinergic signaling.

Authors:  Matthias Zebisch; Norbert Sträter
Journal:  Proc Natl Acad Sci U S A       Date:  2008-05-05       Impact factor: 11.205

8.  8-BuS-ATP derivatives as specific NTPDase1 inhibitors.

Authors:  Joanna Lecka; Irina Gillerman; Michel Fausther; Mabrouka Salem; Mercedes N Munkonda; Jean-Philippe Brosseau; Christine Cadot; Mireia Martín-Satué; Pedro d'Orléans-Juste; Eric Rousseau; Donald Poirier; Beat Künzli; Bilha Fischer; Jean Sévigny
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

9.  Structure-activity relationships of anthraquinone derivatives derived from bromaminic acid as inhibitors of ectonucleoside triphosphate diphosphohydrolases (E-NTPDases).

Authors:  Younis Baqi; Stefanie Weyler; Jamshed Iqbal; Herbert Zimmermann; Christa E Müller
Journal:  Purinergic Signal       Date:  2008-06-05       Impact factor: 3.765

10.  Activity-dependent release of adenosine: a critical re-evaluation of mechanism.

Authors:  Mark Wall; Nicholas Dale
Journal:  Curr Neuropharmacol       Date:  2008-12       Impact factor: 7.363
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.